[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596762":3},{"organization":4,"outcomesModule":7,"designInfo":42,"detailedDescription":41,"studyPopulation":41,"armGroups":50,"interventions":60,"overallOfficials":41,"centralContacts":69,"locations":75,"responsibleParty":92,"collaborators":41,"id":96,"slug":41,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":41,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":119,"whyStopped":41,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Beijing Chao Yang Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":41},[9],{"measure":10,"description":11,"timeFrame":12},"The proportion of patients with a favorable prognosis (mRS score of 0-2 ) after randomization at 90 (±7) days","Modified Rankin Scale (mRS) is defined as the gold standard for measuring global functional outcomes after stroke: 0-1 indicating functional independence, 0-2 favorable prognosis, defining functional independence, 4-5 Severely disabled, 6 death. Higher mRS scores indicate worse prognosis.","Day 90 (±7) post-randomization",[14,18,22,26,29,33,37],{"measure":15,"description":16,"timeFrame":17},"Core infarction volume on Diffusion-Weighted Imaging","The effectiveness of HBO for patients with acute ischemic stroke was evaluated based on the core cerebral infarction volume.","Day 10 (±1）post-randomization",{"measure":19,"description":20,"timeFrame":21},"National Institutes of Health Stroke Scale (NIHSS）score [(0, Normal)-(42, worst)]","The effectiveness of HBO therapy in patients with acute ischemic stroke undergoing endovascular treatment was evaluated based on the improvement rate of NIHSS score day 10 post-randomization.","Day 10(±1) NIHSS score post-randomization",{"measure":23,"description":24,"timeFrame":25},"mRS score [ (0, Normal)-(6, worst)]","To assess the effectiveness of HBO treament for ischemic stroke using mRS score on day 10, 30, 90 and 360 post-randomization","Day 10 (±1）post-randomization; Day 30(±3) post-randomization; Day 180(±14) post-randomization; Day 360(±30) post-randomization.",{"measure":27,"description":28,"timeFrame":12},"Distribution of mRS score [(0, normal)-6(worst)]","mRS (0-1): the proportion of functional independence; mRS (0-2): the proportion of good prognosis; mRS (4-6) : the proportion of severe disability.",{"measure":30,"description":31,"timeFrame":32},"Bartherl index (BI)[(0, worst)-(100, normal)]","Functional independence was assessed using the BI","Day 30(±3), 90(±7) , 180(±14) and 360 (±30) post-randomization",{"measure":34,"description":35,"timeFrame":36},"EuroQol 5-Dimensions(EQ-5D)[(0, worst)-(100, normal)]","Health-related quality of life was measured using EQ-5D.","Day 30(±3), 90(±7), 180(±14), 360(±30) post-randomization",{"measure":38,"description":39,"timeFrame":40},"Stroke recurrence rate","New symptoms persisting for \\> 24 hours and new lension on the DWI.","Day 30(±3) , 90(±7d), 180(±14d) and 360(±30) post-randomization",null,{"allocation":43,"interventionModel":44,"interventionModelDescription":41,"primaryPurpose":45,"observationalModel":41,"timePerspective":41,"maskingInfo":46},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":47,"maskingDescription":41,"whoMasked":48},"SINGLE",[49],"OUTCOMES_ASSESSOR",[51,56],{"label":52,"type":53,"description":41,"interventionNames":54},"hyperbaric oxygen therapy","EXPERIMENTAL",[55],"Other: Hyperbaric Oxygen Therapy",{"label":57,"type":6,"description":41,"interventionNames":58},"Control group",[59],"Other: Conventional therapy group",[61,65],{"type":6,"name":62,"description":63,"armGroupLabels":64,"otherNames":41},"Hyperbaric Oxygen Therapy","1.6 atmosphere absolute (1.6 ATA), HBO treatment administrated via mask or hood, one 60 minutes session, once daily, 5 days a week (can be non consecutive days), with a total of 10 sessions.",[52],{"type":6,"name":66,"description":67,"armGroupLabels":68,"otherNames":41},"Conventional therapy group","Conventional therapy",[57],[70],{"name":71,"role":72,"phone":73,"phoneExt":41,"email":74},"Shuyuan Yuan","CONTACT","+86 18511703665","shuhua_yuan@126.com",[76],{"facility":77,"status":41,"city":78,"state":41,"zip":41,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":87},"Beijing Chaoyang Hospital, Capital Medical University","Beijing","China","CN",{"type":82,"coordinates":83},"Point",[84,85],116.39723,39.9075,{"lat":85,"lon":84},[88],{"name":89,"role":72,"phone":90,"phoneExt":41,"email":91},"Guangxu Liu","+86 010-85231129","bjcyh_yjxbf@163.com",{"type":93,"investigatorFullName":94,"investigatorTitle":95,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"PRINCIPAL_INVESTIGATOR","Jing Yang","Hyperbaric Oxygen Department","100596762",false,"NCT07049692","Hyperbaric Oxygen After Stroke Thrombectomy: A Multicenter Randomized Trial on Safety and Efficacy","Evaluation of the Efficacy and Safety of Hyperbaric Oxygen in Patients After Endovascular Treatment for Acute Ischemic Stroke: A Multicenter, Open-label, Randomized Controlled Clinical Trial","NOTICE-1","Inclusion Criteria:\n\n* 35-75 years\n* The symptoms and signs are consistent with acute anterior circulation ischemic stroke. The immediate postoperative angiographic recanalization grade was ≥ 2b.\n* Neurological deficit score at the time of enrollment: 5 ≤ NIHSS ≤ 15 points\n* Consciousness status (NIHSS 1a-1b items): 0-1 point\n* Pre-stroke functional status (mRS score): 0-1\n* Time from surgery to randomization grouping: ≤ 72 hours\n* Patient or legal representative who signed the informed consent form\n* Preoperative CT angiography or magnetic resonance angiography confirmed large vessel occlusion (internal carotid artery or middle cerebral artery M1 segment) that was consistent with the symptoms and signs; And the area supplied by the middle cerebral artery in the brain is less than 1\u002F3.\n* A lberta S troke P rogram E arly C T S core ≥ 6\n\nExclusion Criteria:\n\n* Subjects with HBO contraindications or intolerance\n* Postprocedural imaging identified either procedure-related subarachnoid hemorrhage or hemorrhagic transformation\n* Based on the medical history, it is suspected that the cerebral embolism is caused by sepsis or infective endocarditis\n* Expected lifespan \\\u003C 90 days\n* Severe heart, liver and kidneys failure\n* Pregnancy\n* Hereditary or acquired bleeding tendency, deficiency of coagulation factors, recent use of oral anticoagulants with an international normalized ratio (INR) \\> 3 or activated partial thromboplastin time (APTT) exceeding the normal value by more than 3 times\n* Baseline platelet count \\\u003C 50×10 9\u002FL\n* Baseline blood glucose is less than 2.78 mmol\u002FL or greater than 22.2 mmol\u002FL.\n* Unstable vital signs (heart rate ≤ 50 beats\u002Fmin or ≥ 120 beats\u002Fmin, oxygen saturation ≤ 90%, respiration ≥ 30 breaths\u002Fmin or ≤ 10 breaths\u002Fmin);\n* Hypertension that cannot be controlled by medication: Systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg;\n* Suspected of having acute myocardial infarction;\n* Currently involving in the research of other projects related to drugs or medical devices.\n* CT or MRI scans revealed intracranial tumors (except for cerebellar meningiomas) and intracranial arteriovenous malformations.\n* Based on the medical history and CT or MRI findings, a diagnosis of internal carotid artery dissection or aortic dissection is suspected;\n* Based on the medical history and CT or MRI findings, cerebral vasculitis is suspected.\n* Based on the clinical evidence of multiple vascular regions being occluded (either in the bilateral anterior circulation or anterior\u002Fposterior circulation) or bilateral infarction or multi-region infarction as detected by CT angiography or magnetic resonance angiography;\n* CT or magnetic resonance imaging shows a significant midline shift effect (\\> 0.5 cm);\n* CT angiography or magnetic resonance angiography confirmed the presence of cerebral vasculitis or cerebral vasculitis syndrome;","ALL","35 Years","75 Years",{"count":107,"type":108},424,"ESTIMATED","INTERVENTIONAL",[111],"NA","1. The goal of this clinical trial is to evaluate the efficacy and safety of hyperbaric oxygen (HBO)in stroke patients after endovascular treatment\n2. The main questions it aims to answer is:\n\n   Whether HBO can improve the prognosis of ischemic stroke patients after endovascular treatment?\n3. Participants will:\n\nreceive HBO (1.6 Atmosphere Absolute，1.6ATA)，Once a day, for 1 hour each time, for 5 days a week (it can be non-consecutive days), the total course of treatment is 10 times.\n\nundergo three scheduled face to face or telephone follow-up assessments during the 12-month period following HBO.",[114],"Acute Ischemic Stroke",[116,117,118],"HBO","acute ischemic stroke","endovascular treatment","NOT_YET_RECRUITING","2025-12-25",{"date":122,"type":123},"2025-12-31","ACTUAL",{"date":125,"type":108},"2026-02-01",{"date":127,"type":108},"2028-03-30",{"name":5,"class":6},1]